

Remibrutinib (LOU064) treatment improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Phase 2b study results

M. Metz, A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh, I. Nikolaev, A. Giménez-Arnau, M. Maurer

Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this [LINK](#) to access the abstract after 11th June 2023, once it is available at the congress website